BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low – What’s Next?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $7.53 and last traded at $7.4950, with a volume of 195346 shares changing hands. The stock had previously closed at $7.78.

Wall Street Analysts Forecast Growth

BBOT has been the subject of several research reports. HC Wainwright raised their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Canaccord Genuity Group began coverage on BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 price objective for the company. Wall Street Zen lowered shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Stifel Nicolaus initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

BridgeBio Oncology Therapeutics Stock Down 4.8%

The firm has a market cap of $593.21 million, a P/E ratio of -3.61 and a beta of 0.29. The firm has a fifty day moving average price of $8.62.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. Analysts anticipate that BridgeBio Oncology Therapeutics, Inc will post -2.32 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BBOT. Geode Capital Management LLC increased its position in shares of BridgeBio Oncology Therapeutics by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after acquiring an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in BridgeBio Oncology Therapeutics during the fourth quarter worth $1,185,000. BIT Capital GmbH acquired a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth about $313,000. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Finally, Renaissance Technologies LLC bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $930,000. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.